Lunai Bioworks Inc. — Form 10-K
Filed October 13, 2026 · analyzed by the Periodic Agent
10-K
— Neutral
significance 28/100
What the filing says
Lunai effected a 1-for-8 reverse stock split effective May 22, 2026 (second reverse split in 8 months; first was 1-for-10 in Sept 2025). Separately, on July 21, 2026, Lunai converted $671,659.45 in debt from three creditors (Ren Sindlev, RS Arving ApS, RS Group ApS) into 239,025 shares of common stock at $2.81/share. Debt comprised three promissory notes (principal $300K to $400K range) plus $24K in trade payables. Series B preferred stock ($20M stated value, 8 shares issued May 1, 2026 for Neurobridge IP merger) remains unconverted pending stockholder approval and contains 4.99% beneficial ownership limitation.
Why this rating
Reverse splits are routine capital structure management. Debt conversion of $672K (~0.6% of $111.9M market cap) reduces burn but dilutes shareholders by ~0.5% post-split. Series B overhang ($20M) is significant structural concern but blocked from conversion.
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.